Knight Therapeutics (TSE:GUD) Sets New 52-Week High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$6.25 and last traded at C$6.18, with a volume of 43828 shares changing hands. The stock had previously closed at C$6.17.

Analyst Upgrades and Downgrades

Separately, Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Two equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Strong Buy” and an average target price of C$7.08.

Knight Therapeutics Price Performance

The company has a fifty day simple moving average of C$5.65 and a 200-day simple moving average of C$5.57. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. The company has a market cap of C$632.19 million, a P/E ratio of -20.87, a PEG ratio of -1,013.50 and a beta of 0.50.

Insider Buying and Selling

In related news, insider Sime Armoyan sold 92,200 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of C$6.15, for a total value of C$567,030.00. Company insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.